Wealth Enhancement Advisory Services LLC Sells 5,238 Shares of Novavax, Inc. (NASDAQ:NVAX)

Wealth Enhancement Advisory Services LLC decreased its position in Novavax, Inc. (NASDAQ:NVAX) by 30.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 11,688 shares of the biopharmaceutical company’s stock after selling 5,238 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Novavax were worth $94,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in NVAX. Rhumbline Advisers grew its holdings in shares of Novavax by 6.7% in the 4th quarter. Rhumbline Advisers now owns 208,464 shares of the biopharmaceutical company’s stock worth $1,676,000 after purchasing an additional 13,024 shares during the last quarter. Beirne Wealth Consulting Services LLC grew its holdings in Novavax by 65.0% during the 4th quarter. Beirne Wealth Consulting Services LLC now owns 16,500 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 6,500 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Novavax by 0.4% during the 4th quarter. Bank of New York Mellon Corp now owns 436,451 shares of the biopharmaceutical company’s stock worth $3,509,000 after acquiring an additional 1,664 shares during the last quarter. NewEdge Wealth LLC grew its holdings in Novavax by 70.1% during the 4th quarter. NewEdge Wealth LLC now owns 170,117 shares of the biopharmaceutical company’s stock worth $1,368,000 after acquiring an additional 70,117 shares during the last quarter. Finally, Oppenheimer & Co. Inc. grew its holdings in Novavax by 262.7% during the 4th quarter. Oppenheimer & Co. Inc. now owns 43,573 shares of the biopharmaceutical company’s stock worth $350,000 after acquiring an additional 31,559 shares during the last quarter. Institutional investors own 53.04% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on NVAX shares. BTIG Research started coverage on shares of Novavax in a report on Friday, February 28th. They set a “buy” rating and a $19.00 price objective on the stock. TD Cowen raised shares of Novavax to a “hold” rating in a report on Thursday, February 27th. B. Riley reaffirmed a “buy” rating on shares of Novavax in a research note on Monday, May 19th. JPMorgan Chase & Co. reduced their target price on shares of Novavax from $9.00 to $7.00 and set an “underweight” rating on the stock in a research note on Friday, May 9th. Finally, Citigroup started coverage on shares of Novavax in a research note on Tuesday. They issued a “sell” rating and a $6.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $17.00.

Novavax Price Performance

Novavax stock opened at $6.49 on Wednesday. The company’s 50 day simple moving average is $6.72 and its 200 day simple moving average is $7.68. Novavax, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $17.81. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of 2.45, a PEG ratio of 0.08 and a beta of 2.80.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share for the quarter, topping the consensus estimate of $0.71 by $2.22. Novavax had a net margin of 38.14% and a negative return on equity of 115.51%. The business had revenue of $666.66 million for the quarter, compared to analyst estimates of $204.08 million. During the same quarter last year, the firm earned ($1.05) EPS. Novavax’s quarterly revenue was up 610.3% compared to the same quarter last year. As a group, analysts predict that Novavax, Inc. will post -1.46 EPS for the current fiscal year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.